Keywords: CDC; Centers for Disease Control and Prevention; CMV; cytomegalovirus; FDA; U.S. Food and Drug Administration; FTA-ABS; fluorescent treponemal antibody-absorption; HAART; highly active antiretroviral therapy; H&E; hematoxylin and eosin; IBD; inflammatory